Rewarding innovation

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

2 November 2015 Est. reading: 4 min read

Hillary Clinton’s tweet in September about drug pricing sent some parts of the US health care sector into a bit of a tailspin, contributing to a renewed sell-off in US biotech in particular. As a global industry, this has also affected sentiment towards health care stocks elsewhere in the world. Clearly, there are examples of drug prices being increased significantly and unjustifiably but we do not view this a major problem for truly innovative pharmaceutical and biotechnology companies, such as the ones in which we have invested.

National US health expenditure accounts for just under 20% of US GDP. The rate has been steadily increasing in recent years and is forecast to continue to do so, by virtue of demographics and lifestyles which are causing a significant increase in the prevalence of decadent western diseases such as diabetes, cancer and cardiovascular disease. These are, of course, issues that are not confined to just the US but the entire developed world and, increasingly, emerging economies which aspire to western standards of living.

Chart showing the US national health expenditure as a percentage of US GDP over time

Prescription drug spending only accounts for approximately 10% of the total healthcare spend in the US but, this too is forecast to increase in the years ahead. Little wonder then that, in an environment of continued public sector budgetary pressure, the subject has become something of a political football.

Prescription drug spending as percentage of US national health expenditure over time

The decrease in prescription drug spending between 2009 and 2013 reflects the ‘patent cliff’ that many pharmaceutical companies have grappled with in recent years. As patents expired, generic competition entered the market at much lower prices, hence the declining proportion of prescription drug spending as a % of total US national health expenditure. The patent cliff headwind is now dissipating, however, so it seems reasonable to expect prescription drug spending to gradually account for more of health expenditure going forward. Furthermore, improving returns on R&D have resulted in an increase in new drug approvals in the last couple of years, a trend that we expect to continue. These innovative new therapies, typically in conditions where there is high unmet medical need, attract justifiably higher prices after many expensive years in development.

Even with high prices, truly innovative therapies can actually help to combat the inexorable rise in health care costs in the US and elsewhere around the world. Innovation can help, and indeed is helping, to turn health conditions that were previously seen as terminal, into chronic or even curable conditions.

For example, hepatitis C is an infectious disease affecting the liver which causes about half a million deaths worldwide per annum. Patients have historically required intensive treatment involving weekly injections over an extended period of time, which ultimately cured about half of patients but caused life-threatening reactions in others. The overall cost of this lengthy and complicated treatment used to be considerable. More recently, however, the standard of care has evolved rapidly thanks to innovative new therapies developed by Bristol-Myers Squibb, Gilead and AbbVie. As a result we now have safer and more effective treatments for hepatitis C which represent a cure for most patients. Although the price of these therapies is high, the overall cost of treating the disease across the health care system is significantly reduced.

Nevertheless, it is also clear that behaviour from a small minority of companies has cast a dark shadow across the entire industry, amid accusations of dramatic and gratuitous price increases. Turing Pharmaceuticals, for example, which was cited in the New York Times article that attracted Mrs Clinton’s attention, bought an old, off patent drug called daraprim and immediately increased its price from $13.50 per tablet to $750! This is legal but it isn’t the result of recent innovation and it certainly doesn’t appear to represent an advance in patient care.

We can understand the consternation that this type of behaviour has caused policy makers and the desire to tackle this issue is clearly proving politically popular. Nevertheless, there is a massive difference between a strategy that is innovation-led and one that is not.

There is a long-term understanding between the pharmaceutical industry and government, particularly in the US, wherein successful scientific research can be rewarded with attractive long-term returns. Innovation leads productivity and productivity is the key to long-term economic growth, so the benefits of scientific research investment are far-reaching and, in the case of health care, bring additional social benefits by improving the lives of patients.

The long-term relationship between the pharmaceutical industry and government is not under threat, in our view. Targeting pharmaceutical & biotech companies broadly on price would result in lower investment, threatening jobs, patients and whole economy productivity. For this reason, a broad attack on drug pricing is not at all likely, in our view.

The debate is likely to rumble on, however, as the US election looms ever nearer and it does have the capacity to challenge market sentiment. We will follow events closely, but we do not expect them to undermine our confidence in the long-term investment case for health care in the US and elsewhere around the world. Indeed, by selectively targeting inappropriate pricing behaviour within the industry, policy initiatives could be beneficial if they allow true innovation to be more fairly rewarded.

What are the risks?

  • The value of the fund and any income from it may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The ongoing charges figure is charged to capital, so the income of the fund may be higher but capital growth may be restricted or capital may be eroded
  • The fund may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits – some of these security types could increase the fund′s volatility and increase the level of indirect charges to which the fund is exposed
  • The fund may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the sterling value of investments to decrease or increase
  • The fund may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund, and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund′s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address Beaufort House, 51 New North Road, Exeter, EX4 4EP.

© 2019 Woodford Investment Management Ltd.
All rights reserved.

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.

Privacy Preference Center

Experience Tracking

Lets our analytics service track you across our different websites and enables data sharing among our different marketing tools.

AMCV_[Tracker ID]@AdobeOrg (Adobe), [Tracker ID]@AdobeOrg (Adobe)
Adobe Analytics (helps us provide you with more relevant experiences and content based on your likely interests). Cookies: demdex, dextp, dpm, DST, DSTJS
Twitter personalisation (by better understanding how devices are related, Twitter can use information from one device to help personalize the Twitter experience on another device). Cookies: personalization_id
Heap Analytics (provides metrics on user behaviour and actions throughout the site). Cookies: _gid, _hp2_id.[Tracker ID],_hp2_props.[Tracker ID], _ga, _mkto_trk, optimizelyBuckets, optimizelyEndUserId, optimizelySegments, raygun4js-userid, _attribution_referrer, _csrf
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: _tmae ,ev_sync_dd,ev_sync_yh,everest_g_v2,gglck

Traffic Metrics

Allows Woodford to aggregate information on website usage and popular content

_ga, _gid
Google Analytics (tracks and reports website traffic and user behaviour): Cookie: CONSENT
New Relic (application and server performance monitoring – allows us to spot problems with our website code and improve them to keep things running smoothly). Cookie: JSESSIONID
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: __qca,__smToken, _ga, _mkto_trk, _rtbmedia

Search History

Populates the 'recent searches' section of the website navigation.

wf__recent_searches_untracked

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?